Found Tirzepatide Review: Cost, Brand vs Compounded & Honest Verdict (2026)

Found is one of the more established weight-care platforms in telehealth — founded in 2019, with 250k+ members and one of the broadest formularies in the category. Unusually, it offers the real FDA-approved brand-name products (Zepbound and Mounjaro) alongside compounded tirzepatide, paired with behavioral coaching. This review covers what Found is, what it dispenses, the brand-versus-compounded picture, its layered pricing, and the catches. We disclose an affiliate relationship with Found; it never changes our scoring, and every fact here comes from Found's own program.

What Found is

Found is an established, physician-designed weight-care platform. Obesity-medicine clinicians review an online intake and prescribe from a wide menu matched to each patient: compounded tirzepatide, the FDA-approved brand-name products (Zepbound and Mounjaro), brand and compounded semaglutide, and oral Rybelsus. Medication is paired with behavioral coaching, an app, a member community, and insurance navigation. Found is available in all 50 states, and HSA/FSA is accepted. Its longer track record and its access to the actual brand drugs are what distinguish it from compounded-only startups.

Brand vs compounded — and why Found's breadth matters

The defining question for any tirzepatide program is which tirzepatide it dispenses:

• •Brand tirzepatide is Eli Lilly's FDA-approved Zepbound (weight management, obstructive sleep apnea) and Mounjaro (type 2 diabetes) — the exact molecule and dose studied in the pivotal trials.
• •Compounded tirzepatide is pharmacy-made, not FDA-approved, and was not the product tested in those trials.

Found is one of the few platforms that can prescribe either, which is a genuine advantage in 2026. The FDA declared the tirzepatide shortage resolved in October 2024, and the enforcement discretion that permitted routine large-scale compounding ended in early 2025 (around February 18, 2025 for 503A pharmacies, March 19, 2025 for 503B outsourcing facilities) — the full timeline is in our guide to whether compounded tirzepatide is still legal in 2026. Because Found can route you to the brand product, you can sidestep the compounded uncertainty entirely if you choose — but confirm in writing which product a given plan dispenses, because that one fact explains most of the price differences you will see.

What Found costs in 2026

Found's pricing is layered rather than flat, which is the main thing to understand before subscribing. A compounded GLP-1 entry point is advertised as low as $99/month, but the cheapest tiers require a 3–12 month prepay; realistic compounded tirzepatide runs roughly $299–$399/month; and the brand-name pathway stacks a membership of about $39/month on top of the medication. Cost and coverage vary by state and plan, so there is no single all-in figure — you should price your specific path.

For the brand route, the benchmark is Lilly's own self-pay channel: LillyDirect sells brand Zepbound single-dose vials at roughly $299–$449/month depending on dose (prices effective February 23, 2026; 28-day supply), and Found's brand pathway adds its membership on top. For the full cash-price picture, see our Zepbound cost and savings guide and our breakdown of Zepbound vials vs pens on self-pay.

How the care model holds up

Found's strengths are among the strongest in this roundup: an established track record since 2019 and real scale (250k+ members), obesity-medicine clinicians, access to the real FDA-approved brand drugs rather than compounded-only, behavioral coaching and a member community, insurance navigation, and 50-state availability with HSA/FSA accepted. The trade-offs are about pricing structure rather than legitimacy: the cheapest compounded rate requires a 3–12 month prepay, the brand pathway stacks a separate ~$39/month membership on top of the medication, and cost and coverage vary by state and plan — so there is no single flat number. As with any GLP-1 service, tirzepatide carries labeled warnings for acute pancreatitis, gallbladder disease, and a boxed thyroid C-cell tumor warning — see our guides on Zepbound side effects, the gallbladder risk, and the thyroid cancer warning.

Does the drug work? (Separate from the provider)

Separate the provider from the medication. Brand tirzepatide's efficacy is trial-grade: in the 72-week SURMOUNT-1 trial, adults without diabetes lost on average roughly 15% to 21% of body weight across the 5–15 mg doses, versus about 3% on placebo¹; against semaglutide in SURMOUNT-5, tirzepatide produced significantly greater weight loss — about 20% versus 14%². Those results apply to the brand molecule (which Found can prescribe); compounded versions were never tested in those trials, so the trial efficacy cannot simply be assumed to transfer. The full picture is in our tirzepatide evidence guide.

The honest verdict

Found is a strong choice if you value an established platform, obesity-medicine clinicians, and the option of the real FDA-approved brand drugs alongside coaching — and you are comfortable pricing a layered rather than flat structure. The main reservations are the pricing shape: the cheapest compounded rate needs a 3–12 month prepay, the brand pathway adds a separate membership, and totals vary by state and plan. If you specifically want the FDA-approved drug, Found is one of the few telehealth routes that can get it — compare its brand all-in against LillyDirect. If you want a single flat compounded price with included support instead, weigh CoreAge Rx. See our best tirzepatide providers ranking and best place to get Zepbound online roundup.